Travere Therapeutics (TVTX) investor relations material

Strategic vision and market opportunity

• Focus on rare kidney and metabolic diseases with three potential treatment standards and a global market projected to exceed $10B.

• Addressable patient populations: >70,000 for IgAN, up to 30,000 for FSGS in the U.S., and 7,000–10,000 for HCU globally.

• Continued pipeline diversification through external innovation and expertise in rare disease therapy development.

Product pipeline and regulatory milestones

• FILSPARI (sparsentan) fully approved for IgAN in the U.S. and under review for FSGS, with a PDUFA target date of January 13, 2026.

• Pegtibatinase in development as a potential first disease-modifying therapy for classical HCU; Phase 3 HARMONY Study enrollment to restart in 2026.

• Global commercial partnerships established for FILSPARI, with launches in Europe and Asia and up to $910M in potential milestone payments.

FILSPARI in IgA nephropathy (IgAN)

• FILSPARI is the only non-immunosuppressive, oral, once-daily therapy proven to significantly slow kidney function decline in IgAN.

• Demonstrated ~50% proteinuria reduction at 36 weeks and ~40% at 2 years in Phase 3 studies, with safety comparable to irbesartan.

• Commercial launch outperformed benchmarks, with $72M U.S. net sales in 2Q25 and high patient access and prescriber adoption.

• Positioned as foundational care in IgAN, supported by evolving KDIGO guidelines recommending earlier intervention.